New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
BACKGROUND
With the limited role of current treatment regimens and potential associated side effects of radiation in young children with ependymoma, considerable effort is being focused on new chemotherapeutic strategies and biologic agents.


CONCLUSIONS
Identification of those molecular changes underlying the development of ependymoma may, in time, lead to the development of not only novel therapeutic agents, but also specific patient-tailored therapies directed against known cell-signaling pathways.
Wright
Karen D
KD
Division of Neuro Oncology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Mailstop 260, Memphis, TN 38105, USA. karen.wright@stjude.org
Gajjar
Amar
A
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D004806:Ependymoma / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D007223:Infant; D011799:Quinazolines / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib